Abstract P32 Table 1

	Monotherapy (n=15)	Combination (n= 8)	Rescue (n=1)
Haemostasis	15/15(100%)	7/8(88%)	0/1
Re-bleeding	3/13(23%)	1/6(17%)	n/a
7-day mortality	1/13(8%)	0	0
30-day mortality	2/13(15%)	0	0

There were no adverse events associated with Hemospray.

Outcomes in the Hemospray treatment subgroups (table 1).

Conclusions Hemospray is safe and effective in LGIB's with 92% haemostasis rates, with better outcomes as a Monotherapy. Anticoagulants have an effect on haemostasis rates (78% vs 100%).

Lower GI bleeds are difficult to treat. Hemospray is an effective alternative in situations where access is difficult and there is a large surface of bleeding.

P33 HEMOSPRAY TREATMENT IN NON-VARICEAL UPPER GASTROINTESTINAL BLEEDS: OUTCOMES FROM THE FIRST 500 HEMOSPRAY REGISTRY PATIENTS

^{1,2}Mohamed Hussein*, ¹Durayd Alzoubaidi, ³Michael Weaver, ²Christwishes Makahamadze, ⁴Alvaro de la Serna, ⁵Jacobo Ortiz Fernandez Sordo, ⁶Johannes W Rey, ⁷Bu Hayee, ⁸Edward Despott, ⁸Alberto Murino, ⁹Sulleman Moreea, ¹⁰Phil Boger, ¹¹Jason Dunn, ¹²Inder Mainie, ²David Graham, ³Dan Mullady, ³Dayna Early, ⁵Krish Ragnunath, ¹³John Anderson, ¹⁴Pradeep Bhandari, ¹⁵Martin Goetz, ⁴Enrique Rodriguez, ¹⁶Tamas Gonda, ⁵Ralf Kiesslich, ¹⁷Emmanuel Coron, ^{1,2}Laurence B Lovat, ^{1,2}Rehan Haidry. ¹University College London, UK; ²University College London Hospital, UK; ³Washington University School of Medicine, USA; ⁴Hospital Universitario Ramón y Cajal, Spain; ⁵Nottingham University Hospitals, UK; ⁶Horst Schmidt Kliniken, Germany; ⁷Kings College Hospital, UK; ⁸Royal Free Hospital, UK; ⁹Bradford Hospital, UK; ¹⁰University Hospital Southampton, UK; ¹¹Guy's and St Thomas Hospital, UK; ¹²Belfast Health and Social Care Trust, UK; ¹³Gloucestershire Hospitals, UK; ¹⁴University of Portsmouth, UK; ¹⁵Klinikum Sindelfingen-Böblingen, Germany; ¹⁶Columbia University, USA; ¹⁷University Hospital of Nantes, France

10.1136/gutjnl-2020-020108

Introduction Upper gastrointestinal bleeding (UGIB) is a leading cause of morbidity. The aim was to look at outcomes in patients with non-variceal UGIBs of all causes treated with Hemospray.

Methods Data was collected prospectively (Jan' 16- Nov'19) from 16 centres in the USA, UK, Germany, France and Spain. Hemospray was used during endoscopy as a monotherapy, dual therapy or rescue therapy. Haemostasis was defined as cessation of bleeding within 5 minutes of Hemospray application.

Results 512 patients with non-variceal UGIBs were recruited (343 male, 169 female). The most common cause was peptic ulcers (236/512, 46%).

Immediate haemostasis was achieved in 473/512 (92%) patients. Median Blatchford was 11 (IQR, 8–14), median Rockall was 7 (IQR, 6–8). Re-bleeding occurred in 59/404 (15%) patients. There was a 7-day mortality (all cause) of 9% (42/444), 30-day mortality (all cause) was 19% (85/444). The highest haemostasis rates were in the Hemospray monotherapy group (95%).

39 patients did not achieve haemostasis (69% were peptic ulcer related). 14/39 (36%) of these patients had CT embolization, 7/39 (18%) managed conservatively and 3/39 (8%) had surgery.

Abstract P33 Table1

	Peptic ulcers (n =236)	Malignancy (n=96)	Post procedure (n=73)	Inflammation (n=20)	Angiodysplasia (n=12)
Median Blatchford (IQR)	13(10–14)	10(7–12)	5(0–9)	9(7–14)	11(9–11)
Median Rockall (IQR)	7(6–8)	8(7–9)	6(5–7)	7(6–8)	6(5–7)
Haemostasis	209/236 (89%)	93/96 (97%)	73/73 (100%)	19/20 (95%)	12/12 (100%)
Re-bleed	34/181 (19%)	11/78 (14%)	2/57 (4%)	2/17 (12%)	2/11 (18%)
7-day mortality	24/208 (12%)	2/81 (2%)	1/59 (2%)	4/18 (22%)	0
30-day mortality	48/208 (23%)	16/81 (20%)	1/59 (2%)	6/18 (33%)	0

Outcomes in different UGI pathologies (table 1).

Conclusion There were high immediate haemostasis rates following treatment of non-variceal UGIBs. The better outcomes were when Hemospray was used in UGIB's post endotherapy, malignancy and Angiodysplasia. In malignancies it can bridge towards surgery/chemoradiotherapy, and post endotherapy it can provide definitive haemostasis with low re-bleed rates.

P34 EFFECT OF BOWEL PREPARATION ON RENAL FUNCTION IN PATIENTS WITH AND WITHOUT CHRONIC KIDNEY DISEASE

Ben Johnson*, Vanja Giljaca. University Hospitals Birmingham, Birmingham, UK

10.1136/gutjnl-2020-020108

Aims Records for patients who underwent colonoscopy and who received a 2L polyethylene glycol (PEG) bowel preparation were reviewed to evaluate whether there is any effect on renal function in those patients with chronic kidney disease (CKD) versus those without.

Methods We screened 1000 randomly chosen patients from a pool of 2128 colonoscopies in 2017. Data were collected on quality of bowel preparation, history of CKD, and creatinine and an estimated glomerular filtration rate (eGFR) in the 60 days before and after colonoscopy. Patients with CKD were defined as those patients with a documented diagnosis or an eGFR of less than 60 for more than 3 months.

Results Bowel preparation quality was good or excellent in 41% of patients. Out of 1,000 patients, only 20.9% (n = 209) had their renal function checked both 60 days before

Abstract P34 Table 1

	No. of Patients	% Creatinine Change	% eGFR Change
Patients with CKD	58	4.70%	2.60%
Patients without CKD	151	1.30%	0.05%
Significance of % Change in CKD vs Non-CKD		p = 0.18	p = 0.18